Core Viewpoint - The Hengqin Guangdong-Macao Deep Cooperation Zone aims to establish a highly coordinated economic system with Macao by 2029, enhancing cross-border flow of various elements and developing key industries, particularly the "Four New" industries [2][3][4]. Group 1: Development Goals - By 2029, the "Four New" industries' added value is expected to increase from 59.4% of the regional GDP in 2024 to 65% [2][3]. - The added value of Macao-funded industries is projected to rise from 3 billion CNY in 2024 to 9 billion CNY [2]. Group 2: Key Industry Focus - The plan emphasizes the development of technology research and high-end manufacturing, aiming to create a technology innovation platform and support the establishment of demonstration bases for industry-university-research collaboration [4]. - In the traditional Chinese medicine sector, the plan includes building a world-class production base and promoting international standards [5]. - The tourism and trade sectors will focus on building an international leisure tourism island and a new international trade center [5]. Group 3: Financial Sector Development - The financial sector will see initiatives to enrich financial services, promote high-quality development, and facilitate cross-border financial innovation [5]. - By 2029, the added value of the modern financial industry is expected to grow from 10.08 billion CNY in 2024 to 11 billion CNY [5]. Group 4: Current Industry Structure - As of the end of 2024, there are 31,685 "Four New" enterprises in the cooperation zone, with a total added value of 31.99 billion CNY [6]. - The current industry structure is still dominated by traditional sectors like real estate and commerce, with emerging industries like technology and high-end manufacturing being underdeveloped [7]. Group 5: Challenges and Recommendations - The cooperation zone faces challenges in achieving a clear industrial division of labor and avoiding homogeneous competition [7]. - Recommendations include enhancing collaboration between government departments, simplifying processes, and establishing risk control mechanisms to ensure safety while promoting openness [8].

Group 1 - The Beijing Economic Development Zone's Science and Technology Financial Service Center has processed 71 technology loan applications totaling 19.8 billion yuan and completed 62 credit approvals amounting to 19.5 billion yuan as of the end of June [1] - The center was officially established on April 1 this year and aims to create a comprehensive financial service system for technological innovation by incorporating various financial institutions such as securities, insurance, and leasing [1][3] - The center has recently upgraded to version 2.0, expanding the number of pilot banks from 7 to 14, which allows for more innovative financial products to support tech enterprises [2] Group 2 - New financial products introduced in version 2.0 include "Technology R&D Loans" and "No Repayment Renewal Loans," in addition to existing products like "Acquisition Loans" and "Talent Loans" [2] - The first "Technology R&D Loan" was successfully issued to Beijing National New Energy Vehicle Technology Innovation Center Co., Ltd., providing 10 million yuan in credit support, significantly alleviating the company's funding pressure for R&D [2] - The loan approval process has been streamlined, reducing the time from application to disbursement to just one month, which is more than a 50% reduction compared to previous timelines, enhancing loan efficiency and reducing costs for enterprises [2]

Core Insights - The article discusses advancements in the field of cyclic peptide libraries, particularly focusing on the DNA-encoded library technology (DELT) which enhances the screening and discovery of novel cyclic peptides with superior properties [1][2]. Group 1: Technology and Methodology - DELT allows for the rapid construction and screening of large compound libraries by linking specific nucleic acid tags to peptide molecules, providing an efficient and cost-effective platform for high-throughput screening of cyclic peptides [1]. - Researchers designed and synthesized eight cyclic peptide sub-libraries, collectively forming a super library containing approximately 100 million different cyclic peptide molecules, utilizing various cyclization methods [2]. Group 2: Research Findings - In screening for the tumor-related protein MDM2, multiple sub-libraries exhibited a consistent enrichment pattern, with specific amino acid sequences showing high binding affinity, achieving a maximum binding activity (Ki) of 11 nM [2]. - The study revealed that some cyclic peptide combinations, which had low enrichment in single sub-libraries, demonstrated good activity after off-DNA synthesis, indicating that single sub-library screening may underestimate the potential of high-activity molecules [2]. Group 3: Specific Case Studies - For the GIT1 screening, no consistent enrichment pattern was observed across different sub-libraries, leading to the identification of two cyclic peptide compounds, one of which effectively blocked the interaction with β-PIX [3]. - The research emphasized the importance of using multiple methods, such as competitive screening and in vitro experiments, to comprehensively validate the authenticity and specificity of the screened compounds [3]. Group 4: Publication and Support - The research findings were published in JACS Au under the title "Influence of Macrocyclization Strategies on DNA-Encoded Cyclic Peptide Libraries," and the work received support from the National Natural Science Foundation of China [3].

Core Viewpoint - The approval of Wuhan Heyuan Biotechnology Co., Ltd. for IPO marks the first successful case under the restarted fifth listing standard of the Sci-Tech Innovation Board, reflecting the regulatory support for innovative technology companies [1][2]. Group 1: Company Overview - Wuhan Heyuan Biotechnology, established in 2006, focuses on the blue ocean market of "recombinant human albumin" and is expected to launch its core product, HY1001, soon after completing Phase III clinical trials [1]. - Currently, Heyuan's revenue primarily comes from pharmaceutical excipients and research reagents, with its core innovative drug still in development and not yet generating income, leading to a loss [2]. Group 2: Industry Context - As of now, 20 companies have utilized the fifth listing standard on the Sci-Tech Innovation Board, with 19 being innovative drug development firms and 1 in high-end medical device development [2]. - In 2024, these 20 companies are projected to achieve a combined revenue exceeding 14 billion yuan, representing a growth of over 40% compared to 2023, with 16 companies generating over 100 million yuan in revenue [2]. - By the first quarter of 2025, these companies continued to show growth, achieving a total revenue of 3.78 billion yuan, a year-on-year increase of 29.27% [2]. Group 3: Regulatory Environment - The implementation of the "1+6" policy measures for the Sci-Tech Innovation Board aims to enhance inclusivity and adaptability in the regulatory framework, promoting deeper integration of technological and industrial innovation [3]. - The pace of IPO applications has accelerated, with over 30 applications received in the first half of the year, of which more than 70% are from the Sci-Tech Innovation Board, facilitating a positive cycle among technology, capital, and industry [3].

Group 1 - Shida Shenghua expects a net loss of 52 million to 60 million yuan for the first half of 2025, a year-on-year decrease of 236.64% to 257.66% [1] - ST Zhizhi's vice president Wang Dong resigned for personal reasons, effective immediately upon delivery of the resignation to the board [1] - Haoyuan Pharmaceutical plans to increase capital by 400 million yuan to its wholly-owned subsidiary through a debt-to-equity swap, raising the registered capital from 400 million to 800 million yuan [1] Group 2 - Longxun Co. announced that shareholders and executives plan to reduce their holdings by up to 2% of the company's shares [2] - Aijian Group confirmed it has not engaged in any stablecoin-related business as of now [3] - Yanghe Co.'s chairman Zhang Liandong resigned due to work adjustments, effective immediately [5] Group 3 - Huanwei New Materials announced a stock suspension due to the major matter that may lead to a change in control [5] - Hualing Cable recently won contracts worth 456 million yuan in the power new energy sector, accounting for 10.97% of its audited revenue for 2024 [6] - Aerospace Changfeng plans to publicly transfer 55.45% of its stake in Aerospace Boke [6] Group 4 - Suzhou Planning is planning to acquire control of Dongjin Aerospace Technology, leading to a stock suspension for up to 10 trading days [6] - Yuexiu Capital intends to increase its stake in Yuexiu Real Estate using up to 204.22 million yuan through the Hong Kong Stock Connect [6] - Baichuan Co.'s actual controller and chairman Zheng Tiejiang is under investigation and has received a detention notice [7] Group 5 - XWANDA plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [8] - ST Aowei reported a loss of approximately 25.04 million yuan in inventory due to poor storage by a third party [8] - Yian Technology plans to increase capital by 120 million yuan to its subsidiary, raising its equity stake from 60% to 72.973% [9] Group 6 - Dongli New Science's wholly-owned subsidiary was applied for bankruptcy reorganization by creditors due to insolvency [11] - Bochuang Technology changed its name to Changxin Bochuang Technology, effective July 2, 2025 [14] - Huayang Co.'s controlling shareholder received a notice of administrative penalty from the China Securities Regulatory Commission [15] Group 7 - Hangzhou Thermal Power's shareholders plan to reduce their holdings by up to 4.09% of the company's shares [16] - Guoke Military Industry's two shareholders plan to reduce their holdings by up to 1.81% of the company's shares [17] - Pangu Intelligent's seven shareholders plan to reduce their holdings by up to 1% of the company's shares [19]

Core Viewpoint - Wuhan Heyuan Biotechnology Co., Ltd. has successfully passed the IPO review despite three consecutive years of losses, marking a significant milestone as the first company to benefit from the reactivation of the fifth set of listing standards for unprofitable enterprises on the Sci-Tech Innovation Board [2][3]. Group 1: Company Overview - Heyuan Biotechnology was established in 2006 and focuses on innovative drug research and development, primarily generating revenue from non-core products such as research reagents, with projected revenue of 25.21 million yuan in 2024 [2]. - The company has reported losses of 144 million yuan, 187 million yuan, and 151 million yuan from 2022 to 2024, totaling over 480 million yuan in cumulative losses [2]. Group 2: Product and Technology - The core product, HY1001 (plant-derived recombinant human serum albumin injection), is a first-class new drug that has completed phase III clinical trials and is expected to be the first domestically approved recombinant human serum albumin drug, addressing the current 60% import dependency in China [3]. - The "rice blood-making" technology, which utilizes rice embryo cell expression systems, has been recognized with a national technology invention award and is seen as a unique technological pathway that combines synthetic biology and medicine [3]. Group 3: Market and Regulatory Context - The fifth set of standards for the Sci-Tech Innovation Board appears tailored for companies like Heyuan Biotechnology, requiring a minimum market value of 4 billion yuan and at least one core product approved for phase II clinical trials [3]. - The successful IPO of Heyuan Biotechnology serves as a potential model for other unprofitable enterprises in cutting-edge fields such as artificial intelligence and biomedicine [2]. Group 4: Risks and Challenges - The company faces several risks, including the need to successfully launch its core product and demonstrate its efficacy to capture the anticipated market share [4]. - Ongoing patent disputes with Ventria Bioscience may hinder international sales and could result in significant compensation costs if the company loses the case [9]. - If profitability is not achieved in the future, the quality of information disclosure and communication with investors may pose substantial challenges [9].

深圳市科思科技股份有限公司 第一条 为了进一步完善深圳市科思科技股份有限公司（以下简称"公司"） 法人治理结构，促进公司规范运作，增强公司决策的独立性和科学性，更好地保 护全体股东特别是中小股东的合法权益，根据《中华人民共和国公司法》、《上 市公司章程指引》、《上海证券交易所科创板股票上市规则》（以下简称"《上 市规则》"）、《上海证券交易所上市公司自律监管指引第5号——交易与关联 交易》等法律、法规、规范性文件以及《深圳市科思科技股份有限公司章程》（以 下简称"《公司章程》"）的有关规定，制定本制度。 第二条 公司关联交易应当遵循以下基本原则： （一）符合诚实信用的原则，保证关联交易的合法性、必要性、合理性和公 允性； （二）公司与关联人之间的关联交易应签订书面协议，协议的签订应遵循平 等、自愿、等价、有偿的原则； （三）与关联方有任何利害关系的董事、股东，在就该关联交易相关事项进 行表决时，应当回避； （四）公司董事会应当根据客观标准判断该关联交易是否对公司有利； （五）不得利用关联交易调节财务指标，损害公司利益。 第三条 公司关联交易，是指公司或者其合并报表范围内的子公司等其他主 体与公司关联人之间发生 ...

合作区将重点推动"四新"产业和澳资产业发展 横琴将加强重点产业规模和发展能级来促进澳门经济适度多元发展。 《规划》明确，到2029年澳门回归祖国30周年时，合作区与澳门经济高度协同、规则深度衔接的制度体系全面确立，市场准入制度高效衔接。各类要素跨境 流动高效便捷，电子围网系统和跨境金融管理体系建立健全，货物"一线放开、二线管住"的体系高效运转，人员出入境高度便利。同时，特色产业发展形成 规模，"四新"产业增加值占地区生产总值比重从2024年的59.4%提升至65%。澳资产业增加值从2024年的30.04亿元增加至90亿元。 6月30日，《横琴粤澳深度合作区产业发展规划（2025—2029年）》（下称《规划》）印发，明确了横琴粤澳深度合作区（下称"合作区"）接下来几年时间 里，在重点产业培育、营商环境建设和琴澳产业一体化等方面的发展思路。 "横琴合作区产业发展的前景，跟同澳门展开深度合作有密切关系。"中山大学岭南学院经济学教授林江告诉第一财经，横琴最重要的机遇是通过粤澳深度合 作，来为澳门中小企业提供一个创新升级的机会。 Film B Har Car . I H T = K HU.U. 上海 Tom The F ...

Core Viewpoint - The successful IPO of Wuhan Heyuan Biotechnology Co., Ltd. marks a significant milestone as the first company to pass the listing review under the fifth set of standards for the Sci-Tech Innovation Board since its restart, reflecting the regulatory support for innovative biotech firms [1][3]. Group 1: Company Overview - Wuhan Heyuan Biotechnology, established in 2006, focuses on the "recombinant human albumin" sector, which is considered a blue ocean market [3]. - The company's core product, HY1001 (recombinant human albumin injection), has completed Phase III clinical trials and is expected to receive approval for market launch soon, potentially becoming the first recombinant human albumin drug in China [3]. - Currently, Heyuan's revenue primarily comes from pharmaceutical excipients and research reagents, with its core innovative drug still in development and not yet generating income, leading to a loss [3]. Group 2: Industry Context - As of now, 20 companies have utilized the fifth set of standards for listing on the Sci-Tech Innovation Board, with 19 being innovative drug development firms and 1 in high-end medical device development [4]. - In 2024, these 20 companies collectively generated over 14 billion yuan in revenue, representing a growth of over 40% compared to 2023, with 16 companies achieving revenues exceeding 1 billion yuan, and 4 surpassing 10 billion yuan [4]. - The first quarter of 2025 saw these companies continue their growth trend, achieving a total revenue of 3.78 billion yuan, a year-on-year increase of 29.27% [4]. - From 2018 to the first quarter of 2025, companies under the fifth set of standards have launched 17 new Class 1 drugs, accounting for approximately 12% of the total number of domestic innovative drugs approved during the same period [4]. Group 3: Regulatory Environment - The successful IPO of Heyuan is seen as a practical example of the China Securities Regulatory Commission's policy to enhance the inclusivity and adaptability of the Sci-Tech Innovation Board, particularly in supporting high-quality technology enterprises [3][4]. - The pace of IPO applications on the Sci-Tech Innovation Board has accelerated, with over 30 applications received in the first half of the year, of which more than 70% are from Sci-Tech Innovation Board companies [5].

整理 | GLP1减重宝典内容团队 6月30日，泰德医药在香港交易所正式挂牌上市，由摩根士丹利与中信证券担任联席保荐人。公司H股发行价定为每股30.60港元，总市值达 43.49亿港元。开盘初期，股价一度上涨近4%，触及31.8港元。 | 30.800+ | 国际 国际 | 32.850 今 开 | 30.300 | | --- | --- | --- | --- | | +0.200 +0.65% | 最低 | 28.100 昨 收 | 30.600 | | | 成交额 2.72亿 市盈率TTM 68.29 总市值 - 43.67亿 | | | | 成交量 | 859.38万股 市盈率(静) 201 | 68.29 总股本 | 1.42亿 | | 换手率 | 11.68% 市净率 1 12.69 流通值 1 | | 22.67亿 | | 52周最高 | 32.850 委 比 -- -- | 51.18% 流通股 | 7360万 | | 52周最低 | 28.100 量 比 | -- 振 幅 幅 -- | 15.52% | | 历史最高 | 32.850 股息TTM | -- 股息率TM | | | 历史最低 ...